These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17361273)

  • 1. Treatment of chronic orbital myositis with daclizumab.
    Garcia-Pous M; Hernández-Garfella ML; Díaz-Llopis M
    Can J Ophthalmol; 2007 Feb; 42(1):156-7. PubMed ID: 17361273
    [No Abstract]   [Full Text] [Related]  

  • 2. Biologic therapies for inflammatory eye disease.
    Lim L; Suhler EB; Smith JR
    Clin Exp Ophthalmol; 2006; 34(4):365-74. PubMed ID: 16764659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of recalcitrant psoriasis with daclizumab.
    Wohlrab J; Fischer M; Taube KM; Marsch WC
    Br J Dermatol; 2001 Jan; 144(1):209-10. PubMed ID: 11167723
    [No Abstract]   [Full Text] [Related]  

  • 4. Orbital granulomatous giant cell myositis: a case report and review.
    Selva D; Dolman PJ; Rootman J
    Clin Exp Ophthalmol; 2000 Feb; 28(1):65-8. PubMed ID: 11345351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of idiopathic orbital inflammatory disease with cyclosporine-A: a case presentation.
    Zacharopoulos IP; Papadaki T; Manor RS; Briscoe D
    Semin Ophthalmol; 2009; 24(6):260-1. PubMed ID: 19954381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated.
    Immunotherapy; 2010 Jul; 2(4):437. PubMed ID: 20635996
    [No Abstract]   [Full Text] [Related]  

  • 7. Orbital involvement in multifocal fibrosclerosis.
    Kyhn M; Herning M; Prause JU; Heegaard S
    Acta Ophthalmol Scand; 2004 Jun; 82(3 Pt 1):323-4. PubMed ID: 15115462
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-CD25 antibodies (daclizumab) as renal sparing immunosuppression after liver transplantation.
    Alakkari A; Maguire D; Geoghegan J; Hegarty JE; Traynor O; Watson A; McCormick PA
    Aliment Pharmacol Ther; 2011 Mar; 33(5):615-6; author reply 616-7. PubMed ID: 21255044
    [No Abstract]   [Full Text] [Related]  

  • 9. Humanized monoclonal anti-CD25 antibody as a novel therapeutic option in HIV-associated psoriatic erythroderma.
    Dichmann S; Mrowietz U; Schöpf E; Norgauer J
    J Am Acad Dermatol; 2002 Oct; 47(4):635-6. PubMed ID: 12271320
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of orbital myositis with adalimumab (Humira).
    Adams AB; Kazim M; Lehman TJ
    J Rheumatol; 2005 Jul; 32(7):1374-5. PubMed ID: 15996084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis.
    Tomaske M; Amon O; Bosk A; Handgretinger R; Schneider EM; Niethammer D
    Med Pediatr Oncol; 2002 Feb; 38(2):141-2. PubMed ID: 11813188
    [No Abstract]   [Full Text] [Related]  

  • 12. Orbital myositis after delivery.
    Hiraga A; Uzawa A; Kamitsukasa I
    Clin Neurol Neurosurg; 2008 Mar; 110(3):316-7. PubMed ID: 18055101
    [No Abstract]   [Full Text] [Related]  

  • 13. Anticipated benefits and surprising effects of daclizumab in multiple sclerosis.
    Stüve O; Greenberg BM
    Lancet Neurol; 2010 Apr; 9(4):337-8. PubMed ID: 20163991
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab in the treatment of recalcitrant idiopathic orbital inflammation.
    Wilson MW; Shergy WJ; Haik BG
    Ophthalmic Plast Reconstr Surg; 2004 Sep; 20(5):381-3. PubMed ID: 15377906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on anti-CD25: daclizumab in MS.
    Schippling DS; Martin R
    Int MS J; 2008 Sep; 15(3):94-8. PubMed ID: 18808743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
    ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ
    Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.
    Busse WW; Israel E; Nelson HS; Baker JW; Charous BL; Young DY; Vexler V; Shames RS;
    Am J Respir Crit Care Med; 2008 Nov; 178(10):1002-8. PubMed ID: 18787222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic monoclonal antibody therapy (daclizumab) in the treatment of cicatrizing conjunctivitis in stevens-johnson syndrome, refractory to conventional therapy.
    Fiorelli VM; Dantas PE; Jackson AT; Nishiwaki-Dantas MC
    Curr Eye Res; 2010 Dec; 35(12):1057-62. PubMed ID: 20929291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclizumab: a novel therapeutic option in severe bullous pemphigoid.
    Mockenhaupt M; Grosber M; Norganer J
    Acta Derm Venereol; 2005; 85(1):65-6. PubMed ID: 15848995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.